在非区域性淋巴腺病变的食道癌症中生存率:倾向性得分匹配分析
James Tankel1, Rawan Sakalla1, Neyla Boukhili1
1Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
概括
对于患有第四期胰腺癌的食管癌患者来说,回性淋巴结的参与不会影响新辅助疗法和手术后的生存结果. 然而,关节上淋巴腺病与较差的存活率有关.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 在接受新辅助疗法和切除的患有第四期非区域性淋巴腺病的食道癌患者的生存数据有限.
- 这项研究比较了非区域性淋巴结核病患者的生存率与与本地区域性疾病的倾向匹配队列相比.
研究的目的:
- 为了评估食道癌患者的生存结果,患有IV期非区域性淋巴腺病,接受新辅助疗法和手术切除治疗.
- 为了将这些结果与患有局部区域性疾病的患者的倾向匹配队列进行比较.
主要方法:
- 来自加拿大上胃肠道癌症网络的前性维护数据库 (2010年1月至2022年12月) 的回顾性队列分析.
- 确定了放射性可疑的非区域性逆关节或关节上淋巴腺病变的患者,并且倾向性得分与没有非区域性疾病的对照组相匹配 (1:1).
主要成果:
- 在1235名患者中,39名患者符合纳入标准;35名 (89%) 患有腺癌. 在67%和33%的患者中,分别存在复原皮质和关节上淋巴腺病.
- 复原皮质淋巴腺病变 (21.0个月) 与对照组 (27.0个月;P=.262) 的平均整体存活时间相似,但在关节上部疾病 (13.0个月;P=.039) 中明显差.
- 切除后,54%的人在非区域性淋巴结站实现了ypN0. 研究组的中位随访时间为40.1个月,对照组为70.0个月.
结论:
- 在第四阶段食道癌的逆淋巴腺病似乎不会在多式疗法治疗时对生存结果产生负面影响.
- 具有治愈意图的多式疗法可能是选择性食道癌患者的合适选择,这些患者患有回性淋巴腺病变.
- 在这种情况下,关节上淋巴腺病与较差的生存结果有关,需要进一步调查.
相关概念视频
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Comparing the Survival Analysis of Two or More Groups
181
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
181


